Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Hepatology. 2018 Dec;68(6):2197–2211. doi: 10.1002/hep.30097

Figure 4. Liver-directed inhibition of ACC improves hepatic insulin sensitivity.

Figure 4

(A) Plasma glucose and glucose infusion rate (GIR) during a hyperinsulinemia-euglycemic clamp (4 mU/[kg-min]) insulin) in rats fed a high fat diet supplemented with 1% sucrose drinking water (HFSD) for 3 days and treated with 10 mg/kg/day Compound 1 (ACCi) or vehicle control for 21 days (n = 10 per group). (B) Insulin-stimulated glucose disposal (Rd). (C) Endogenous glucose production (EGP) during the basal and steady-state period of the clamp. (D) Hepatic acetyl-CoA levels in basal (overnight fasted) and clamped rats treated as in (A). (E) Insulin-mediated suppression of EGP during the clamp. (F) Insulin-mediated suppression of plasma non-esterified fatty acids (NEFAs) during the clamp. In all panels, n = 10 per treatment group. Data are presented as mean ± SEM. *P ≤ 0.05 by unpaired student's t-test compared to vehicle control.